RIVANNA continued to advance its imaging portfolio this week, highlighted by a major expansion of its Accuro XV clinical program across U.S. academic medical centers. The portable, volumetric ultrasound platform is being evaluated for AI-enabled fracture detection, with the broader dataset expected to support a faster FDA 510(k) submission timeline.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The study has grown from two to eight sites in four months, with 10 systems now deployed at institutions including UCSF, Yale, and UT Southwestern, and 666 patients enrolled to date. Early, unpublished data suggest Accuro XV imaging may offer patient-experience benefits versus X-ray in select emergency settings, particularly among patients who did not receive analgesia.
The expansion is linked to the exercise of a funding option by BARDA, part of ASPR within the U.S. Department of Health and Human Services, underscoring federal interest in the platform’s potential for emergency and surge-care use. The multi-center work is building a large 3D imaging database to train RIVANNA’s CADe/x automated fracture detection algorithm and validate its BoneEnhance bone visualization module.
RIVANNA emphasizes that leading emergency medicine investigators at high-volume hospitals are driving the study, reinforcing its strategy of validating Accuro XV in complex care environments. Executives also highlight the rapid scaling of the program as evidence of operational agility and strong relationships with academic centers, which could support commercial uptake if clearance is secured.
Beyond fracture care, the company is also promoting AI-enabled trends in neuraxial anesthesia, focusing on decision support, imaging guidance, and workflow optimization. By positioning itself around data, training, and software-driven solutions, RIVANNA is signaling a broader move toward higher-value, recurring revenue models in anesthesia and emergency imaging markets.
Overall, the week’s developments point to accelerating clinical and regulatory momentum for Accuro XV, backed by government support and academic partnerships, while the company simultaneously builds thought leadership and software-oriented positioning in neuraxial anesthesia.